India is ready to step in as an alternative site for early-stage clinical trials to help mitigate the impact of disruptions ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Experts discuss the crucial role of government in enhancing India's participation in clinical trials at BioAsia 2025 panel.

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing ...

We think it can be appropriate to present phase 2 trial participation as offering a small prospect of benefit,” researchers wrote. About 16% of patients enrolled in phase 2 cancer trials receive a ...

Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" ...

Spanish biopharmaceutical company Biofabri and nonprofit scientific research organization IAVI announced today that the first ...

Initiated the Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa ...

Glenda Gray, program director of a research consortium, talked with STAT about the impact of the funding freeze on an HIV ...

Eikon is building a high-profile line of potential drugs. Its portfolio is led by EIK-1001, which is just rolling out a ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed” or the "Company”) today ...